Simulations Plus, Inc. Stock

Equities

SLP

US8292141053

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 02:19:47 2024-06-13 pm EDT 5-day change 1st Jan Change
48.2 USD -2.14% Intraday chart for Simulations Plus, Inc. +3.56% +8.65%
Sales 2024 * 69.13M Sales 2025 * 83.77M Capitalization 984M
Net income 2024 * 12M Net income 2025 * 16M EV / Sales 2024 * 14.2 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 11.8 x
P/E ratio 2024 *
78.6 x
P/E ratio 2025 *
60.8 x
Employees 195
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.13%
1 week+4.24%
Current month+1.45%
1 month-0.22%
3 months+14.11%
6 months+20.07%
Current year+9.36%
More quotes
1 week
45.23
Extreme 45.23
50.11
1 month
44.48
Extreme 44.48
51.22
Current year
35.98
Extreme 35.98
51.22
1 year
32.69
Extreme 32.69
52.69
3 years
32.58
Extreme 32.575
67.59
5 years
26.00
Extreme 26
90.92
10 years
5.27
Extreme 5.27
90.92
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 18-06-25
Founder 79 96-07-16
Director of Finance/CFO 61 20-11-30
Members of the board TitleAgeSince
Founder 79 96-07-16
Director/Board Member 74 17-04-30
Director/Board Member 56 14-12-02
More insiders
Date Price Change Volume
24-06-13 48.42 -1.71% 81 290
24-06-12 49.26 +6.92% 184,473
24-06-11 46.07 -0.84% 70,969
24-06-10 46.46 +0.52% 64,877
24-06-07 46.22 -1.55% 48,198

Delayed Quote Nasdaq, June 13, 2024 at 12:51 pm EDT

More quotes
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
49.26 USD
Average target price
55.33 USD
Spread / Average Target
+12.33%
Consensus